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Available online 05 April 2018Spinocerebellar ataxia type 1 (SCA1) is a hereditary neurodegenerative disease causedby a CAG repeat expansion
in exon 8 of the ATXN1 gene. We generated induced pluripotent stem cells (hiPSCs) from a SCA1 patient and his
non-affected sister by using non-integrating Sendai Viruses (SeV). The resulting hiPSCs are SeVfree, express
pluripotency markers, display a normal karyotype, retain the mutation (length of the CAG repeat expansion in
the ATXN1 gene) and are able to differentiate into the three germ layers in vitro.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(continued)Resource table.A
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lternative names of
stem cell linesC
ELUMCi002-A: LUMC0113iATAX06 and 113-6
LUMCi002-B: LUMC0113iATAX07 and 113-7
LUMCi002-C: LUMC0113iATAX08 and 113-8
LUMCi003-A: LUMC0114iCTRL01 and 114-1
LUMCi003-B: LUMC0114iCTRL02 and 114-2stitution Leiden University Medical Center (LUMC), Leiden, The
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distributorDr. Ronald A.M. Buijsen (R.A.M.Buijsen@lumc.nl)pe of cell lines hiPSC
rigin Human
ell source Fibroblasts
lonality Clonal
ethod of
reprogrammingNon-integrating Sendai virusultiline rationale Control (2 clones) and disease (3 clones) pair
ene modiﬁcation No
pe of modiﬁcation N/An).
. This is an open access article under thessociated diseaseCC BY-NC-ND license (htSpinocerebellar ataxia type 1 (SCA1)
ene/locus ATXN1/6p22.3
ethod of modiﬁcation N/A
ame of transgene or
resistanceN/Aducible/constitutive
systemN/Aate archived/stock date November 30, 2017
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thical approval The study was approved by the LUMC medical ethics
committee (NL45478.058.13/P13.080) and informed
consent was obtained from both SCA1 patient and his
non-affected sister.Resource utility
These newly generated hiPSCs are useful to study SCA1 disease
mechanisms and therapeutic intervention strategies.
Resource details
Spinocerebellar ataxia type 1 (SCA1) is a rare, autosomal dominant,
neurodegenerative disease clinically characterized by progressive
ataxia, dysphagia, oculomotor disturbance, pyramidal and extrapyrami-
dal symptoms, sensory deﬁcits as well as mild cognitive decline (Sasakitp://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of lines.
hiPSC line names Abbreviation in ﬁgures Gender Age Ethnicity Genotype of ATXN1 locus (#CAG repeats) Disease
LUMCi002-A 113-6 Male 43 Caucasian 29/46 SCA1
LUMCi002-B 113-7 Male 43 Caucasian 29/46 SCA1
LUMCi002-C 113-8 Male 43 Caucasian 29/47 SCA1
LUMCi003-A 114-1 Female 49 Caucasian 29/30 Non-affected control
LUMCi003-B 114-2 Female 49 Caucasian 29/30 Non-affected control
126 R.A.M. Buijsen et al. / Stem Cell Research 29 (2018) 125–128et al., 1996). SCA1 is caused by a CAG triplet repeat expansion in exon 8
of the ATXN1 gene located on chromosome 6p22-p23 (Orr et al., 1993).
In this study, dermal ﬁbroblasts were obtained from a 43 year old man
diagnosed with SCA1 and his 49 year old non-affected sister. Fibroblasts
were successfully reprogrammed into hiPSCs by using a replication-
defective and persistent Sendai virus (SeV) vector installed with OCT4,
SOX2, KLF4, and c-MYC (Nishimura et al., 2011). The three patient-
derived hiPSC clones derived from SCA1 ﬁbroblast line SCA1 2A were
named LUMCi002-A, LUMCi002-B, and LUMCi002-C. The two clones de-
rived from control ﬁbroblast line SCA1 2B of the non-affected sister
were named LUMCi003-A and LUMCi003-B (Table 1). All hiPSCs showed
a typical ES cell like morphology with small and tightly packed cells, a
high nucleus to cytoplasm ratio, and well deﬁned nucleoli (Fig. 1A). Fur-
thermore, all hiPSCs were SeVfree at passage 5 (data not shown) and
stained positive for the pluripotency markers Oct3/4, Nanog, and SSEA-
4 (Fig. 1B). Accordingly, the expression of the pluripotency genes OCT4,
NANOG, and SOX2 was upregulated in hiPSCs compared to ﬁbroblasts
(Fig. 1C). A routine Global Screening Array showed (GSA) no major
copy number variations or allelic changes between the original ﬁbroblast
cell line and related hiPSC cell lines (Fig. 1D). The CAG repeat size was
conﬁrmed by PCR (Fig. 1E) and fragment analysis (data not shown) in
these newly established hiPSC lines. Furthermore, all generated hiPSC
lines were able to differentiate into all three germ layers in vitro as con-
ﬁrmed by immunoﬂuorescent staining for the endodermal marker α-
fetoprotein (AFP), the mesodermal marker PECAM-1 (CD31), and the ec-
todermal marker β3-tubulin (TUBB3) (Fig. 1F). The presence of myco-
plasma was tested regularly and all cell lines were negative
(Supplementary Fig. S1). All data is present in Table 2.Materials and methods
Ethical statement
This study was approved by the LUMC scientiﬁc ethical committee
and informed consent was obtained from both SCA1 patient and his
non-affected sister (NL45478.058.13/P13.080).Generation of hiPSCs
A skin biopsy was obtained from a 43 year old male SCA1 patient and
his 43 year old sister. After dissection ﬁbroblast were cultured inmedium
containing minimum essential medium supplemented with 15% FBS,
2 mM GlutaMAX and 1% penicillin-streptomycin (all ThermoFisher) at
37 °C and 5% CO2, expanded to passage three and frozen for future use.
For reprogramming 1 × 105 ﬁbroblasts were infected with 7.5 MOI
SeVdp(KOSM)302 L and seeded on irradiated mouse embryonic ﬁbro-
blasts (MEFs) in ﬁbroblast media 24 h after transduction. Starting the
next day, cells were cultured in DMEM/F12 Glutamax medium with 20%
KnockOut Serum Replacement (KOSR), Non-Essential Amino Acids
(NEAA), 2-mercapthoethanol, Pen/Strep (all Gibco) and 10 ng/ml bFGF
(Peprotech) until hiPSC colonies emerged about 3 weeks later. hiPSC col-
onies were picked manually and expanded on Vitronectin XF in TESR-E8
media according to manufacturer's instructions (STEMCELL Technolo-
gies) (Table 1).Spontaneous in vitro differentiation of hiPSCs
Aggregates of undifferentiated hiPSCs were harvested using Gentle
Cell Dissociation Reagent STEMCELL Technologies) and plated on
Vitronectin XF coated glass coverslips in TESR-E8 media according to
manufacturer's instructions (STEMCELL Technologies). Cells were cul-
tured in DMEM/F12 with 20% FBS for three weeks with media changes
every other day.Immunoﬂuorescent staining
hiPSCs were ﬁxed in 2% paraformaldehyde for 30 min, RT, perme-
abilized with 0.1% Triton X-100, blocked in 4% normal swine serum
(NSS, DAKO) for 1 h at RT and incubated with primary antibodies in 4%
NSS o/n at 4 °C followed by incubation with secondary ﬂuorescent dye-
labelled antibodies for 1 h at RT. DAPI was used as nuclear counter stain-
ing. Antibodies are listed in Table 2. Imagesweremade on a Leica TCS SP8.RNA isolation and RT-qPCR
RNA isolation was performed using the ReliaPrep™Miniprep Sys-
tem (Promega) according to the manufacturer's instructions. 500 ng
RNA/reaction was reverse transcribed using the transcriptor ﬁrst strand
cDNA synthesis kit (Roche). qRT-PCR reactions were run on a
LightCycler® 480 Real-Time PCR System (Roche) with SensiMix SYBR
Hi-ROX Kit (Bioline). Cycle parameters were an initial denaturation of
10 min at 95 °C, followed by 45 cycles of denaturation at 95 °C for
10 s, annealing at 60 °C for 30 s and extension at 72 °C for 20 s. CT-
values were normalized to GAPDH using the ΔΔCT-method. Primer se-
quences are listed in Table 3.DNA isolation
Genomic DNA isolation was performed using the Wizard Genomic
DNA Puriﬁcation Kit (Promega) according to the manufacturer's
instructions.Repeat length PCR
The CAG repeat in exon 8 of the ATXN1 genewas ampliﬁed to deter-
mine the genotype of the hiPSCs. Cycling conditions were an initial de-
naturation of 4 min at 95 °C, followed by 35 cycles of 30 s 95 °C, 30 s 60
°C and 1 min 72 °C. The primers are listed in Table 2.Fragment length analysis
Fragment length analysis was carried out with OneTaq Master Mix
(New England Biolabs) on a ABI genetic analyser (ThermoFisher). Cy-
cling conditions were an initial denaturation of 5 min at 94 °C, followed
by 35 cycles of 30 s 94 °C, 1 min 60 °C and 2 min 68 °C. The primers are
listed in Table 2.
Fig. 1. Characterization of SCA1 hiPSCs LUMCi002-A, B, and C and unaffected sibling control hiPSCs LUMCi003-A and B.
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Table 2
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Phase contrast microscopy Normal Scale bar represents 1000 μm Fig. 1 panel A
Phenotype Qualitative analysis of
immunoﬂuorescent staining
Positive staining of pluripotency markers: Oct-3/4, Nanog, SSEA-4 Scale bar
represents 100 μm
Fig. 1 panel B
Quantitative analysis by
RT-qPCR
Expression of pluripotency markers: OCT4, NANOG, SOX2 Fig. 1 panel C
Genotype GSAMD24 v1 Illumina
Inﬁnium Snp array 700 k
CNV report resolution 150 kb: No major copy number variations or allelic
changes LUMCi002-A, B, and C: 46 XY LUMCi003-A and B: 46 XX
Fig. 1 panel D
Identity GSAMD24 v1 Illumina
Inﬁnium Snp array 700 k
DNA Proﬁling: Performed Data not shown but available from author
Fibroblasts and derived hiPSCs have N99% identical SNPs Submitted in archive with journal
Mutation
analysis
Repeat length PCR and
fragment analysis
Fibroblasts and derived hiPSCs have similar CAG repeat lengths Fig. 1 panel E (PCR) and data not shown but
available from author (fragment analysis)
Southern Blot OR WGS N/A
Microbiology
and virology
Mycoplasma Mycoplasma testing by luminescence: Negative Supplementary Fig. S1
Spontaneous
Differentiation
Qualitative analysis of
Immunoﬂuorescent staining
Positive staining of germ layer markers: AFP (endoderm), CD31 (mesoderm),
β3-tubulin (ectoderm) Scale bar represents 100 μm
Fig. 1 panel F
Donor screening N/A
Genotype
additional info
Blood group genotyping N/A
HLA tissue typing N/A
Table 3
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency
markers
mouse IgG2b anti-Oct-3/4 1:100 Santa Cruz Biotechnology Cat# sc-5279, RRID:AB_628051
mouse IgG1 anti-Nanog 1:150 Santa Cruz Biotechnology Cat# sc-293121, RRID:
AB_2665475
mouse IgG3 anti-SSEA-4 1:30 BioLegend Cat# 330402, RRID:AB_1089208
Differentiation
markers
mouse IgG2a anti-β3-tubulin 1:4000 Covance Research Products Inc. Cat# MMS-435P, RRID:
AB_2313773
mouse anti-CD31 1:100 Dako Cat# M0823, RRID:AB_2114471
rabbit IgG anti α-fetoprotein (AFP) 1:25 Quartett, Cat# 2011200530, RRID:AB_2716839
Secondary
antibodies
Goat anti-Mouse IgG2b Cross-Adsorbed Secondary Antibody, Alexa Fluor 647 1:250 Thermo Fisher Scientiﬁc Cat# A-21242, RRID:AB_2535811
Goat anti-Mouse IgG3 Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 1:250 Thermo Fisher Scientiﬁc Cat# A-21151, RRID:AB_2535784
Goat anti-Mouse IgG1 Cross-Adsorbed Secondary Antibody, Alexa Fluor 568 1:250 Thermo Fisher Scientiﬁc Cat# A-21124, RRID:AB_2535766
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa
Fluor 568
1:500 Thermo Fisher Scientiﬁc Cat# A-11031, RRID:AB_144696
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody,
Alexa Fluor 488
1:500 Thermo Fisher Scientiﬁc Cat# A-21206, RRID:AB_2535792
Primer
Target Forward/Reverse primer (5′–3′)
SeV based vectors (qPCR) SeV GCAGCTCTAACGTTGTCAAA/CCTGGAGCAAATTCACCATGA
GAPDH TCCTCTGACTTCAACAGCGA/GGGTCTTACTCCTTGGAGGC
Pluripotency Markers (qPCR) NANOG CAGTCTGGACACTGGCTGAA/CTCGCTGATTAGGCTCCAAC
OCT4 TGTACTCCTCGGTCCCTTTC/TCCAGGTTTTCTTTCCTAGC
SOX2 GCTAGTCTCCAAGCGACGAA/GCAAGAAGCCTCTCCTTGAA
House-Keeping Genes (qPCR) GAPDH AGCCACATCGCTCAGACACC/GTACTCAGCGGCCAGCATCG
Genotyping by Repeat length PCR ATXN1 TGGAGGCCTATTCCACTCTG/TGGACGTACTGGTTCTGCTG
Targeted mutation analysis (Fragment length analysis) ATXN1 CCCCAACCGCCAACCCC/GTGGGATCATCGTCTGGTGGG
128 R.A.M. Buijsen et al. / Stem Cell Research 29 (2018) 125–128Mycoplasma detection
The presence ofmycoplasmawas tested using theMycoAlert™Myco-
plasma Detection Kit (Lonza) according to the manufacturer's
instructions.SNP array
The Global Screening Array (Illumina) was used according to stan-
dard protocols, followed by a standard analysis in GenomeStudio soft-
ware (Illumina) with the GSA manifest ﬁles. GenomeStudio
Finalreports were used to analyze and visualize in Nexus Discovery
(BioDiscovery El Segundo).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2018.03.018.Acknowledgements
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